This page shows the latest myopia news and features for those working in and with pharma, biotech and healthcare.
The outside view, however, is that our American neighbours struggle more deeply than others. Perhaps it is due to partisan politics and political myopia.
success. Other areas they will look at include the rate of change of myopia in children, conditions that impact children's eyesight and predictive outcomes of refractive surgery.
The US FDA has said it will use its six-month review process for Roche's Lucentis as a treatment for choroidal neovascularization in patients with severe near-sightedness (myopia).
Meanwhile, it has also been filed in Europe for the treatment of diabetic macular oedema and in Japan for choroidal neovascularisation caused by pathologic myopia (mCNV).
Novartis already sells anti-VEGF (vascular endothelial growth factor) drug Lucentis (ranibizumab) for wet AMD - as well as other indications such as pathological myopia and macular oedema - and achieved sales of
The Lucentis guidance covers the use of the medicine to treat sight problems caused by choroidal neovascularisation (CNV) in people with a rare form of short-sightedness known as pathological myopia. ... Pathological myopia is a chronic form of myopia,
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Go beyond multichannel rep myopia: include stakeholders beyond target HCPs. Invest in marketing technology and high-quality data.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...